Atypical clinical manifestation of antiphospholipid syndrome

2009 ◽  
Vol 119 (1-2) ◽  
pp. 99-103
Author(s):  
Robert Krysiak ◽  
Agnieszka Kędzia ◽  
Bogusław Okopień
Nephron ◽  
1993 ◽  
Vol 64 (3) ◽  
pp. 479-480 ◽  
Author(s):  
J. Lacueva ◽  
R. Enríquez ◽  
J.B. Cabezuelo ◽  
M.D. Arenas ◽  
A. Teruel ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2972-2972
Author(s):  
Thomas L. Ortel ◽  
Fatih Cagri Sarikaya ◽  
Ahmet Alptekin ◽  
Karen E. Hansen ◽  
Robert A.S. Roubey ◽  
...  

Abstract Abstract 2972 Poster Board II-950 Background: Antiphospholipid syndrome (APS) is characterized by venous and/or arterial thromboembolic events, recurrent fetal loss, and persistently elevated antiphospholipid antibody (aPL) levels. Familial clustering of individuals with elevated aPL levels occurs, and up to 37% of patients with APS have one or more relatives with at least one clinical feature of APS. Individuals with elevated aPL levels or APS are also frequently identified in families with other autoimmune (AI) disorders, such as lupus or rheumatoid arthritis. Individuals with different autoimmune disorders appear to share common susceptibility loci, suggesting that a common set of susceptibility genes may contribute to clinically distinct autoimmune disorders. To investigate the heritability of APS, we are enrolling patients with APS who have one or more family members affected by APS (multiplex APS) or by other, non-APS, autoimmune disorders (multiplex AI). This study summarizes clinical characteristics of probands and family members enrolled to date in these two groups. Methods: Probands meeting clinical and laboratory criteria for APS (Miyakis, et al. J.Thromb.Haemost, 2006;4: 295-306) who had at least one clinically affected relative positive for either APS or another autoimmune disorder (e.g., lupus, rheumatoid arthritis) were recruited and enrolled into the study. A detailed personal and family history was obtained and relevant family members were also approached to participate in the study. Blood specimens were collected for genetic, serologic, and coagulation testing. Results: Review of more than 200 potential participants identified 13 probands with multiplex APS families and 49 with multiplex AI families. Probands from both groups more frequently had primary rather than secondary APS, and thromboembolic events were the most common clinical manifestation. Catastrophic APS was reported in 1 multiplex APS proband and 4 multiplex AI probands. Proband characteristics are summarized in the Table. In the multiplex APS families, 1 to 3 family members had APS, and the most common clinical manifestation was thromboembolism. In addition, 8 multiplex APS families also had one or more family members who were affected with other autoimmune disorders, most commonly lupus and rheumatoid arthritis. In the multiplex AI families, 1 to 8 family members were affected by a variety of autoimmune disorders, including lupus, Hashimoto's disease, Sjögren's syndrome, rheumatoid arthritis, myasthenia gravis, type I diabetes mellitus, and other diseases. Affected family members most commonly included siblings and/or parents of the probands. Conclusions: In the participants enrolled to date, probands with APS who belonged to multiplex APS or multiplex AI families most commonly had primary APS, and thromboembolic complications were the most common clinical manifestation. Families that were multiplex AI were more common than families that included more than one family member affected with APS, and families that were multiplex APS frequently included members that had other autoimmune disorders. Disclosures: No relevant conflicts of interest to declare.


2012 ◽  
Vol 103 (9) ◽  
pp. 832-833 ◽  
Author(s):  
M.R. Perelló-Alzamora ◽  
J.C. Santos-Duran ◽  
A. Santos-Briz ◽  
P. Unamuno

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xiaojuan Zou ◽  
Zhongqi Fan ◽  
Ling Zhao ◽  
Weiling Xu ◽  
Jin Zhang ◽  
...  

Abstract Background Antiphospholipid syndrome (APS) is an acquired pre-thrombotic autoimmune condition, which produces autoantibodies called antiphospholipid antibodies (APL) against phospholipid-binding plasma proteins. The diagnosis of APS requires at least one of Sapporo standard clinical manifestations and one laboratory criteria (persistently medium/high titer anticardiolipin antibodies, and/or medium/high titer anti-β2-glycoprotein I antibodies, and/or a positive lupus anticoagulant test). Gastrointestinal lesions are rarely reported in APS patients. APS cases with recurrent abdominal pain as the first clinical manifestation are even rarer. Case presentation This report describes an APS case with recurrent abdominal pain as the first clinical manifestation of antiphospholipid syndrome. The patient has a history of two miscarriages. Computed tomography of the abdomen confirmed mesenteric thrombosis and intestinal obstruction while laboratory tests for serum antiphospholipid and anti-β2-glycoprotein I antibodies were positive. This led to the diagnosis of APS. Conclusions This paper provides useful information on gastrointestinal manifestations and APS, also including a brief literature review about possible gastrointestinal symptoms of APS.


Lupus ◽  
2013 ◽  
Vol 22 (3) ◽  
pp. 320-323 ◽  
Author(s):  
O Shovman ◽  
P Langevitz ◽  
B Gilburd ◽  
Y Shoenfeld

2012 ◽  
Vol 103 (9) ◽  
pp. 832-833
Author(s):  
M.R. Perelló-Alzamora ◽  
J.C. Santos-Duran ◽  
A. Santos-Briz ◽  
P. Unamuno

Sign in / Sign up

Export Citation Format

Share Document